About this Research Topic
Tumors of the liver are one of the most common cancer types worldwide. Over recent decades the rate of incidence of liver malignancies has increased considerably, and now is the 7th most common cancer, with an incidence of 9.5 per 100,000 across both sexes, worldwide. Several different neoplasms can develop in the liver, with the most common being hepatocellular carcinoma (HCC), followed by cholangiocarcinoma. Whilst these tumors originate in the liver itself, it is more common for cancers originating elsewhere to metastasise to the liver.
Liver tumors can be caused by a number of different factors, including viral infection with HBV/HCV, lifestyle factors (e.g. excessive alcohol consumption), cirrhosis, and various inherited liver diseases.
Surgery remains the standard form of treatment for both primary and secondary tumors, resulting in the best long-term survival rates. The treatment regime will depend on the stage and type of malignancy, with transplantation being a potential option too for some patients. The extent of hepatectomy and resection range will vary depending on numerous factors, such as but not limited to, the location of the tumor within the organ, overall liver function, and spread to nearby vasculature. There are several ongoing and completed clinical trials investigating potential application of adjuvant and neo-adjuvant treatment to improve curability and prolong survival rates. Ongoing research is also further exploring the feasibility and safety of repeat resection in recurrent liver tumors, which remains as one of the most important curative options for recurrence.
This Research Topic welcomes experimental and clinical submissions related to novel insights and developments in the surgical treatment of HCC and liver tumors including, but not limited to advances in hepatectomy, portal vein embolization & ligation, supportive therapy, combination therapy, surgical pathology, neo- and adjuvant treatment options, and technological advances.
Liver tumors can be caused by a number of different factors, including viral infection with HBV/HCV, lifestyle factors (e.g. excessive alcohol consumption), cirrhosis, and various inherited liver diseases.
Surgery remains the standard form of treatment for both primary and secondary tumors, resulting in the best long-term survival rates. The treatment regime will depend on the stage and type of malignancy, with transplantation being a potential option too for some patients. The extent of hepatectomy and resection range will vary depending on numerous factors, such as but not limited to, the location of the tumor within the organ, overall liver function, and spread to nearby vasculature. There are several ongoing and completed clinical trials investigating potential application of adjuvant and neo-adjuvant treatment to improve curability and prolong survival rates. Ongoing research is also further exploring the feasibility and safety of repeat resection in recurrent liver tumors, which remains as one of the most important curative options for recurrence.
This Research Topic welcomes experimental and clinical submissions related to novel insights and developments in the surgical treatment of HCC and liver tumors including, but not limited to advances in hepatectomy, portal vein embolization & ligation, supportive therapy, combination therapy, surgical pathology, neo- and adjuvant treatment options, and technological advances.
Keywords: HCC, Liver Tumor, Cholangiocarcinoma, Hepatectomy, PVE, PVL, Adjuvant therapy, Neoadjuvant therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
